Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit].
Markina UA, Fomina DS, Lebedkina MS, Kruglova TS, Chernov AA, Zagrebneva AI, Mutovina ZY, Karaulov AV, Alexeeva EI, Lysenko MA. Markina UA, et al. Among authors: lebedkina ms. Ter Arkh. 2022 Jun 17;94(5):675-682. doi: 10.26442/00403660.2022.05.201690. Ter Arkh. 2022. PMID: 36286968 Russian.
Treatment of atopic dermatitis with upadacitinib: adcare single center experience.
Fomina DS, Mukhina OA, Mikhailova VI, Lebedkina MS, Sedova EL, Bobrikova EN, Elisyutina OG, Fedenko ES, Nurpeisov TT, Karaulov AV, Lysenko MA, Ensina LFC. Fomina DS, et al. Among authors: lebedkina ms. Front Med (Lausanne). 2024 Apr 17;11:1385720. doi: 10.3389/fmed.2024.1385720. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38695023 Free PMC article.
[Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study].
Lebedkina MS, Fomina DS, Mutovina ZY, Mаrkina UA, Bogomolov PO, Chulanov VP, Lysenko MA, Alexeeva EI. Lebedkina MS, et al. Ter Arkh. 2023 Aug 17;95(6):494-499. doi: 10.26442/00403660.2023.06.202297. Ter Arkh. 2023. PMID: 38158969 Russian.
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
Fomina DS, Lebedkina MS, Iliukhina AA, Kovyrshina AV, Shelkov AY, Andreev SS, Chernov AA, Dolzhikova IV, Kruglova TS, Andrenova GV, Tukhvatulin AI, Shcheblyakov DV, Karaulov AV, Lysenko MA, Logunov DY, Gintsburg AL. Fomina DS, et al. Among authors: lebedkina ms. Front Immunol. 2023 Oct 20;14:1259725. doi: 10.3389/fimmu.2023.1259725. eCollection 2023. Front Immunol. 2023. PMID: 37928549 Free PMC article. Clinical Trial.
Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study.
Kocatürk E, Salameh P, Sarac E, Vera Ayala CE, Thomsen SF, Zuberbier T, Ensina LF, Popov TA, van Doorn MBA, Giménez-Arnau AM, Asero R, Criado PR, Aarestrup FM, AbdulHameed Ansari Z, Al Abri S, Al-Ahmad M, Al Hinai B, Allenova A, Al-Nesf M, Altrichter S, Arnaout R, Bartosińska J, Bauer A, Bernstein JA, Bizjak M, Bonnekoh H, Bouillet L, Brzoza Z, Calvalcanti Dela Bianca Melo AC, Campinhos FL, Carne E, Purayil SC, Cherrez-Ojeda I, Chong-Neto HJ, Christoff G, Conlon N, Jardim Criado RF, Cvenkel K, Damadoglu E, Danilycheva I, Day C, de Montjoye L, Demir S, Ferucci SM, Fomina D, Fukunaga A, Garcia E, Gelincik A, Göbel JH, Godse K, Gonçalo M, Gotua M, Grattan C, Gugala A, Guillet C, Kalyoncu AF, Karakaya G, Kasperska-Zając A, Katelaris CH, Khoshkhui M, Kleinheinz A, Kolacinska-Flont M, Kolkhir P, Košnik M, Krasowska D, Kumaran MS, Kuprys-Lipinska I, Kurowski M, Kuznetsova EV, Larenas-Linnemann D, Lebedkina MS, Lee Y, Makris M, Gómez RM, Nasr I, Neisinger S, Oda Y, Kara RÖ, Palitot EB, Papapostolou N, Salvador Parisi CA, Pesque D, Peter J, Petkova E, Ridge K, Rudenko M, Rutkowski K, Saini SS, Salman A, Sanchez J, Şekerel B, Serdotetskova SA, Serpa FS, Dikicier BS, Sidiropoulos N, S… See abstract for full author list ➔ Kocatürk E, et al. Among authors: lebedkina ms. J Allergy Clin Immunol. 2023 Nov;152(5):1095-1106. doi: 10.1016/j.jaci.2023.07.019. Epub 2023 Aug 12. J Allergy Clin Immunol. 2023. PMID: 37574079
[Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].
Roppelt AA, Lebedkina MS, Chernov AA, Kruglova TS, Mukhina OA, Yukhnovskaya YD, Samedova FA, Mаrkina UA, Andrenova GV, Karaulov AV, Lysenko MA, Fomina DS. Roppelt AA, et al. Among authors: lebedkina ms. Ter Arkh. 2023 Feb 24;95(1):78-84. doi: 10.26442/00403660.2023.01.202088. Ter Arkh. 2023. PMID: 37167118 Russian.